INVA

InnovivaC

Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences

At close

2026-06-02

View Chart

AI scenario view

RankAlpha Sentiment Codex

B+

Bull case

25%

Probability

Target price

$33.20

+55.5% vs current

Most likely

Base case

50%

Probability

Target price

$24.00

+12.4% vs current

B-

Bear case

25%

Probability

Target price

$16.00

-25.1% vs current

AI sentiment snapshot

Latest data as of 2026-05-20

AI commentary

Primary-source evidence is constructive but still thin: the Q1 release was solid, cash is ample, and the 2H26 NUZOLVENCE launch plus repurchases provide visible support, yet royalty pressure and non-recurring investment gains keep this in monitoring mode. No fresh analyst revision set was available in the checked materials, and no social-context packet was provided.

RankAlpha Sentiment Codex - 2026-05-20

Open full AI memo

Evidence flagged

No evidence quality warning is currently attached to this memo.

Impact

standard

Confidence

AI events

2026-05-18eventBoard refresh tied to Syndeio focus is a minor governance eventMedium impact

The May 18 8-K says Derek Small and Mark DiPaolo resigned from the board to focus on Syndeio, and the company said the resignations did not relate to any disagreement with Innoviva; the filing also adds Josephine Linden to the board [#8-K-2026-05-18].

2026-05-20eventQ1 2026 print confirmed solid growth but mixed royalty mixMedium impact

Innoviva reported Q1 2026 total revenue of $98.0 million (+11% y/y), net product sales of $41.4 million (+37% y/y), cash and cash equivalents of $603.1 million, and net income of $186.6 million driven in part by fair-value gains; this is constructive, but part of the earnings strength is non-cash and should not be extrapolated blindly [#IR-2026-05-06].

2026-08-31catalystOngoing repurchases can cushion volatilityMedium impact

The company repurchased 971,066 shares for $20.4 million in Q1 and has repurchased 1,198,921 shares for $25.0 million since inception of the $125 million program, so continued buyback execution can provide incremental support if operating trends stay stable [#IR-2026-05-06].

View full catalyst timeline

Recommendation

N/A

No formal recommendation provided.

Open AI Memo

As of 2026-05-20 • Updated nightlySource: Internal modelMethodology